Pacira BioSciences (PCRX) Competitors $24.71 +0.94 (+3.95%) As of 01:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PCRX vs. PRGO, SUPN, NKTR, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRKShould you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry. Pacira BioSciences vs. Its Competitors Perrigo Supernus Pharmaceuticals Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Do institutionals and insiders hold more shares of PRGO or PCRX? 95.9% of Perrigo shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.7% of Perrigo shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend PRGO or PCRX? Perrigo currently has a consensus target price of $33.00, suggesting a potential upside of 43.82%. Pacira BioSciences has a consensus target price of $25.75, suggesting a potential upside of 4.08%. Given Perrigo's higher possible upside, research analysts plainly believe Perrigo is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perrigo 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Pacira BioSciences 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 Which has better valuation & earnings, PRGO or PCRX? Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerrigo$4.37B0.72-$171.80M-$1.31-17.52Pacira BioSciences$700.97M1.59-$99.56M-$2.78-8.90 Is PRGO or PCRX more profitable? Perrigo has a net margin of -1.86% compared to Pacira BioSciences' net margin of -18.08%. Pacira BioSciences' return on equity of 13.29% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Perrigo-1.86% 9.09% 3.96% Pacira BioSciences -18.08%13.29%6.61% Does the media prefer PRGO or PCRX? In the previous week, Pacira BioSciences had 1 more articles in the media than Perrigo. MarketBeat recorded 18 mentions for Pacira BioSciences and 17 mentions for Perrigo. Pacira BioSciences' average media sentiment score of 0.80 beat Perrigo's score of -0.03 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Pacira BioSciences 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PRGO or PCRX? Perrigo has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. SummaryPacira BioSciences beats Perrigo on 12 of the 16 factors compared between the two stocks. Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCRX vs. The Competition Export to ExcelMetricPacira BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.11B$2.98B$5.46B$9.66BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-8.9018.0730.0324.98Price / Sales1.59175.32375.7076.70Price / Cash5.1941.8335.9458.58Price / Book1.477.278.155.67Net Income-$99.56M-$54.43M$3.25B$265.39M7 Day Performance12.10%0.33%1.13%2.51%1 Month Performance6.73%5.51%2.83%1.85%1 Year Performance10.64%10.70%28.39%24.09% Pacira BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCRXPacira BioSciences3.0676 of 5 stars$24.71+4.0%$25.75+4.2%+6.4%$1.11B$700.97M-8.89720Earnings ReportPRGOPerrigo4.693 of 5 stars$28.12-1.1%$33.00+17.4%-17.8%$3.91B$4.34B-21.478,379News CoverageEarnings ReportAnalyst ForecastSUPNSupernus Pharmaceuticals1.7983 of 5 stars$33.41-0.5%$36.00+7.8%+29.9%$1.88B$661.82M30.10580Analyst ForecastNKTRNektar Therapeutics4.1761 of 5 stars$23.65-5.4%$88.33+273.5%+22.9%$310.17M$98.43M-2.46220News CoverageEarnings ReportGap UpOMEROmeros3.8525 of 5 stars$4.15+8.4%$18.00+333.7%-8.9%$224.41MN/A-1.57210Gap UpHigh Trading VolumeASMBAssembly Biosciences3.7803 of 5 stars$19.50+5.1%$33.00+69.2%+68.1%$141.68M$28.52M-3.13100Earnings ReportUpcoming EarningsGap UpCPIXCumberland Pharmaceuticals1.028 of 5 stars$3.48-1.1%N/A+121.6%$52.59M$37.87M-13.9280Earnings ReportGap DownLLYEli Lilly and Company4.9741 of 5 stars$807.78-0.6%$1,012.56+25.4%-17.1%$770.22B$45.04B65.7347,000Trending NewsEarnings ReportAnalyst DowngradeGap UpJNJJohnson & Johnson4.6842 of 5 stars$166.18-1.3%$174.50+5.0%+7.9%$404.94B$88.82B17.77138,100Positive NewsABBVAbbVie4.6817 of 5 stars$188.47-1.0%$211.29+12.1%+6.0%$336.11B$56.33B80.2055,000Trending NewsAnalyst UpgradeInsider TradeMRKMerck & Co., Inc.4.9978 of 5 stars$84.16-0.6%$108.69+29.1%-28.6%$212.71B$64.17B12.2575,000Positive News Related Companies and Tools Related Companies Perrigo Competitors Supernus Pharmaceuticals Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors AbbVie Competitors Merck & Co., Inc. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
